Literature DB >> 15704051

Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

Sylvie Naveau1, Bruno Raynard, Vlad Ratziu, Annie Abella, Françoise Imbert-Bismut, Djamila Messous, Fabienne Beuzen, Frédérique Capron, Dominique Thabut, Mona Munteanu, Jean Claude Chaput, Thierry Poynard.   

Abstract

BACKGROUND & AIMS: The aim of this study was to determine the diagnostic use of noninvasive markers of fibrosis in patients with chronic alcoholic liver disease.
METHODS: A total of 221 consecutive patients with an alcohol intake of >50 g/day (median, 100 g/day) and available liver biopsy examination and FibroTest FibroSure (FT) results were included prospectively. Fibrosis was assessed blindly on a 5-stage histologic scale similar to that of the METAVIR scoring system. Hyaluronic acid was measured and used as a standard serum marker of fibrosis.
RESULTS: Advanced fibrosis (F2-F4) was present at biopsy examination in 63% of patients. The mean FT value (SE) was F0 = .29 (.05); F1 = .29 (.03), F2 = .40 (.03), F3 = .53 (.04); and F4 = .88 (.02) (P < .05 between all groups, except between F0 and F1). As opposed to FT, there was no significant difference for hyaluronic acid between F2 and F1 and between F2 and F0. For F2-F4 vs. F0-F1, the FT area under the ROC curves (AUROC) = .84 (.03) and .79 (.03) for hyaluronic acid. For the diagnosis of F4, the AUROC was very high, .95 for FT and .93 for hyaluronic acid. The discordances of the 2 stages were attributed to biopsy failures in 26 cases and to FT failures in 13 cases.
CONCLUSIONS: In heavy drinkers, FT is a simple and noninvasive quantitative estimate of liver fibrosis. The use of FT may decrease the need for liver biopsy examination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15704051     DOI: 10.1016/s1542-3565(04)00625-1

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  36 in total

1.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

Review 2.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Saumya Jayakumar; Stephen A Harrison; Rohit Loomba
Journal:  Curr Hepatol Rep       Date:  2016-04-21

Review 5.  Liver fibrosis markers of nonalcoholic steatohepatitis.

Authors:  Hirayuki Enomoto; Yukihiro Bando; Hideji Nakamura; Shuhei Nishiguchi; Masafumi Koga
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 6.  Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

Authors:  Rosa Lombardi; Elena Buzzetti; Davide Roccarina; Emmanuel A Tsochatzis
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

7.  Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice.

Authors:  Mohamed H Hessien; Ismaiel M El-Sharkawi; Ahmed A El-Barbary; Doha M El-Beltagy; Ned Snyder
Journal:  BMC Gastroenterol       Date:  2010-06-01       Impact factor: 3.067

8.  Assessment of liver fibrosis: noninvasive means.

Authors:  Thierry Poynard; Rachel Morra; Patrick Ingiliz; Françoise Imbert-Bismut; Dominique Thabut; Djamila Messous; Mona Munteanu; Julien Massard; Yves Benhamou; Vlad Ratziu
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

Review 9.  Effect of ethanol on inflammatory responses. Implications for pancreatitis.

Authors:  Gyongyi Szabo; Pranoti Mandrekar; Shilpa Oak; Julia Mayerle
Journal:  Pancreatology       Date:  2007-06-21       Impact factor: 3.996

Review 10.  Liver fibrosis markers in alcoholic liver disease.

Authors:  Lech Chrostek; Anatol Panasiuk
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.